Your Guide to Eylea for Retinal Disease
How Eylea Works
Eylea targets the underlying process that causes vision loss in several serious retinal diseases. It works by interrupting the chain of events that leads to fluid buildup and swelling in the back of the eye.
Many retinal conditions involve a protein called vascular endothelial growth factor, or VEGF. When the retina is damaged or under stress, it produces excess VEGF, which signals the body to grow new blood vessels in the eye. These abnormal blood vessels are fragile and tend to leak fluid or blood into the retina, causing swelling in the macula, the part of the retina responsible for sharp central vision. Without treatment, this swelling can damage retinal cells and lead to lasting vision loss.
Aflibercept works as a decoy receptor, sometimes called a VEGF trap. It binds to VEGF-A and placental growth factor (PlGF) before these proteins can reach blood vessel cells and trigger abnormal growth. By capturing these proteins, aflibercept stops the signal that drives leakage and swelling in the retina. Over time, the retina can begin to dry out and stabilize, and many patients experience improved or stabilized vision as a result.
The FDA has approved Eylea for several retinal conditions, all of which involve abnormal VEGF activity. These include wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR), and myopic choroidal neovascularization (myopic CNV), which is abnormal blood vessel growth related to severe nearsightedness. Your retina specialist can confirm which of these conditions applies to your situation and whether Eylea is the right fit for you.
What the Clinical Evidence Shows
Eylea has been studied in multiple large clinical trials across its approved conditions. The results from these trials helped establish Eylea as a standard of care for serious retinal disease.
Eylea was evaluated in two large clinical trials called VIEW 1 and VIEW 2, which together enrolled thousands of patients with wet AMD. Results showed that Eylea was as effective as another leading anti-VEGF treatment, Lucentis (ranibizumab), at preventing significant vision loss, with similar safety profiles. These findings helped make Eylea one of the primary treatment options for wet AMD.
The VISTA and VIVID trials tested Eylea in patients with diabetic macular edema. In the VISTA trial, a significantly higher percentage of patients treated with Eylea improved on the Diabetic Retinopathy Severity Scale compared to those who received laser treatment alone. These results showed that Eylea offered meaningful benefits over traditional laser therapy for this common and vision-threatening condition.
The COPERNICUS and GALILEO trials studied Eylea for central retinal vein occlusion (CRVO), a blockage in the main vein draining the retina, and found that patients receiving Eylea gained significantly more vision than those receiving sham injections. The VIBRANT trial similarly showed greater visual improvement with Eylea compared to laser treatment for branch retinal vein occlusion (BRVO). These results led to FDA approval for both types of retinal vein occlusion.
What the Injection Experience Is Like
Many patients feel understandably anxious about the idea of an eye injection. In practice, the procedure is brief, well-tolerated, and performed with care to minimize discomfort at every step.
Your retina specialist will numb your eye using anesthetic drops or a small injection of numbing medication before any other steps are taken. The surface of the eye is then cleaned with an antiseptic solution to reduce the risk of infection. You may feel a slight cold or wet sensation during the cleaning process, but this preparation takes only a few minutes.
The entire injection takes about five to ten minutes from start to finish. Your retina specialist uses a very thin needle to deliver the medication through the white part of the eye into the vitreous cavity, which is the gel-filled space inside the eye. Most patients feel pressure rather than sharp pain, and the actual injection itself lasts only a few seconds.
After the injection, mild discomfort or a gritty sensation is common. Some patients notice temporary blurring or see small floaters, which are small specks or shapes drifting across the field of vision. These effects usually resolve within a few hours to a day. Your retina specialist may check your eye pressure before you leave the office, and discomfort tends to decrease with repeated treatments over time.
Treatment Schedule and Dosing
Eylea treatment follows a structured schedule designed to build an effective level of medication in the eye and then maintain that protection over time. Your treatment plan will be tailored to your specific condition and how your retina responds.
Treatment typically begins with a series of monthly injections called the loading phase. For wet AMD, this usually means one injection every four weeks for the first three months, while for diabetic macular edema, loading doses may continue monthly for the first five months. This initial phase helps establish a strong therapeutic level of the medication in the eye.
After the loading phase, your retina specialist will determine how often you need continued injections based on your condition, your response to treatment, and how your retina looks on imaging. Standard-dose Eylea is typically given every four to eight weeks for ongoing maintenance, and some patients can gradually extend the time between injections as their condition stabilizes.
Eylea HD (high-dose aflibercept, 8 mg) was approved by the FDA in 2023 for wet AMD, DME, and diabetic retinopathy, and received additional FDA approval for retinal vein occlusion in November 2025. This higher-dose formulation allows for extended dosing intervals of 8 to 16 weeks after the initial loading phase. For many patients, this means fewer office visits and injections while maintaining the same level of vision protection.
Benefits and Risks of Eylea
Like any medical treatment, Eylea carries both meaningful benefits and potential risks. Your retina specialist will review these with you in detail before starting treatment so you can make a fully informed decision.
Eylea can stabilize vision and, in many cases, improve it. Clinical trials have shown that the majority of patients maintain their vision over time with consistent treatment, and some patients experience meaningful gains in their ability to read, drive, and carry out daily activities. The primary goal of treatment is to control disease activity and preserve as much vision as possible.
The most common side effects after an Eylea injection include eye redness, mild pain or discomfort, floaters, and a feeling of something in the eye. These are usually temporary and resolve on their own within a few days. Temporary blurred vision immediately after the procedure is also common and expected.
Serious complications from intravitreal (inside-the-eye) injections are uncommon but possible. These include eye infection (endophthalmitis), retinal detachment, increased eye pressure, and bleeding inside the eye. There is also a small risk of blood clots in rare cases. Contact your retina specialist or go to the emergency room immediately if you experience sudden vision loss, increasing pain, or worsening redness after an injection.
How Eylea Compares to Other Anti-VEGF Treatments
Several effective anti-VEGF medications are available for retinal disease, and your retina specialist will select the one best suited to your individual needs. Understanding the landscape of options can help you have a more informed conversation with your care team.
In addition to Eylea, other anti-VEGF options include Lucentis (ranibizumab), Avastin (bevacizumab, used off-label for eye conditions), and Vabysmo (faricimab), a newer agent that targets both VEGF and a second protein called angiopoietin-2. Multiple aflibercept biosimilars, which are medications highly similar to the original product, have also received FDA approval in recent years and may offer additional choices for patients.
Your retina specialist considers several factors when selecting a medication, including your specific diagnosis, your treatment history, how your retina responds to medication, and the convenience of the dosing schedule. Switching medications is common if the initial treatment does not produce the desired results, and this is a normal part of managing complex retinal disease.
After Your Injection: What to Expect
Recovery after an Eylea injection is typically straightforward, and most patients return to their normal routine the same day. Knowing what is normal and what requires immediate attention helps you stay on top of your care between visits.
Your vision may be blurry for several hours due to the numbing drops and the injection itself. Avoid rubbing your eye for the rest of the day, and follow any instructions your retina specialist provides about antibiotic eye drops, which are sometimes prescribed for a few days after the injection. Most normal activities can resume right away.
Your retina specialist will schedule regular follow-up appointments to monitor your retina using imaging tests such as optical coherence tomography (OCT), a scan that shows detailed cross-sections of the retinal layers and detects fluid or swelling. Based on these results, your specialist will adjust your treatment schedule as needed. Consistent follow-up is one of the most important factors in achieving the best possible outcomes.
Certain symptoms after an injection require urgent evaluation. See your retina specialist or go to the emergency room right away if you experience sudden vision loss, severe eye pain that worsens over time, increasing redness that does not improve, new floaters or flashes of light, or a curtain or shadow across part of your vision. These could signal a serious complication that needs prompt treatment.
Frequently Asked Questions
Below are answers to questions our patients often ask about Eylea treatment. If you have a question that is not addressed here, our team is happy to help.
Treatment duration depends on your specific condition and how your retina responds over time. Many retinal diseases require ongoing treatment for months or even years to keep disease activity under control. Your retina specialist will work with you to find the longest safe interval between injections, which can reduce the overall burden of treatment while still protecting your vision.
Eylea can improve vision in some patients, and the likelihood of improvement is generally higher when treatment begins early. However, it may not fully restore vision that has been lost due to long-term retinal damage. The primary goal is to stabilize your condition and prevent further deterioration, which is why starting treatment as soon as it is indicated tends to produce better outcomes.
Missing an injection can allow fluid to build up again in the retina, which may cause your vision to worsen between visits. Contact your retina specialist as soon as possible to reschedule rather than waiting for your next scheduled appointment. Staying on your prescribed treatment schedule gives you the best chance of maintaining stable vision over the long term.
Eylea is approved for wet AMD, which involves abnormal blood vessel growth and fluid leakage beneath the retina. Dry AMD and its advanced form, geographic atrophy, involve different disease processes and require different treatments. Complement inhibitors such as Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) are approved specifically for geographic atrophy. Your retina specialist can explain which treatment category applies to your specific diagnosis.
Eylea HD contains a higher dose of aflibercept (8 mg compared to the standard 2 mg) and is designed to provide longer-lasting coverage in the eye after each injection. After completing the loading phase, many patients on Eylea HD can be treated every 8 to 16 weeks rather than every 4 to 8 weeks, which can mean significantly fewer visits over the course of a year. Your retina specialist can evaluate whether the extended-interval formulation is appropriate for your condition and lifestyle.
Some patients notice improvement within the first few months of treatment, particularly after the loading phase is complete. Others experience stabilization rather than a noticeable gain, which is still a meaningful outcome for conditions that would otherwise continue to worsen. Individual responses vary, so it is important to attend all scheduled visits and allow your retina specialist to track your progress with imaging before drawing conclusions about how well the treatment is working for you.
Expert Retina Care at Rhode Island Eye Institute
Our retina specialists at Rhode Island Eye Institute, Dr. Gaurav Gupta and Dr. Pranjal Thakuria, provide advanced, individualized care for patients with wet AMD, diabetic eye disease, retinal vein occlusion, and other serious retinal conditions. With multiple locations across Rhode Island and southeastern Massachusetts, our team is here to offer the subspecialty expertise and ongoing support you need to protect your vision. We welcome you to schedule a consultation and take the next step toward preserving your sight.